Peter Hansen/iStock via Getty Images
Moderna’s (NASDAQ:MRNA) Q3 results confirmed on Thursday that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (NYSE:PFE) and GSK (NYSE:GSK), is shrinking.
Cambridge, Massachusetts-based Moderna (NASDAQ:MRNA), the last of the trio to report Q3 results, reported $10M
